Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT COLEMAN and SHERRY WU.
Connection Strength
0.432
-
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.
Score: 0.052
-
NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735.
Score: 0.048
-
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.
Score: 0.044
-
Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.
Score: 0.040
-
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.
Score: 0.039
-
Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.
Score: 0.039
-
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123.
Score: 0.038
-
Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.
Score: 0.035
-
XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97.
Score: 0.033
-
Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.
Score: 0.032
-
Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
Score: 0.031